Presence of Middle Cerebellar Peduncle Sign in FMR1 Premutation Carriers Without Tremor and Ataxia. by Famula, Jessica L et al.
UC Davis
UC Davis Previously Published Works
Title
Presence of Middle Cerebellar Peduncle Sign in FMR1 Premutation Carriers Without 
Tremor and Ataxia.
Permalink
https://escholarship.org/uc/item/2q94f7r2
Journal
Frontiers in neurology, 9(AUG)
ISSN
1664-2295
Authors
Famula, Jessica L
McKenzie, Forrest
McLennan, Yingratana A
et al.
Publication Date
2018
DOI
10.3389/fneur.2018.00695
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
CASE REPORT
published: 22 August 2018
doi: 10.3389/fneur.2018.00695
Frontiers in Neurology | www.frontiersin.org 1 August 2018 | Volume 9 | Article 695
Edited by:
Maria Salsone,
Consiglio Nazionale Delle Ricerche
(CNR), Italy
Reviewed by:
Fabiana Novellino,
Consiglio Nazionale Delle Ricerche
(CNR), Italy
Hitoshi Okazawa,
Tokyo Medical and Dental University,
Japan
*Correspondence:
Randi J. Hagerman
rjhagerman@ucdavis.edu
Specialty section:
This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neurology
Received: 29 March 2018
Accepted: 31 July 2018
Published: 22 August 2018
Citation:
Famula JL, McKenzie F,
McLennan YA, Grigsby J, Tassone F,
Hessl D, Rivera SM,
Martinez-Cerdeno V and
Hagerman RJ (2018) Presence of
Middle Cerebellar Peduncle Sign in
FMR1 Premutation Carriers Without
Tremor and Ataxia.
Front. Neurol. 9:695.
doi: 10.3389/fneur.2018.00695
Presence of Middle Cerebellar
Peduncle Sign in FMR1 Premutation
Carriers Without Tremor and Ataxia
Jessica L. Famula 1,2, Forrest McKenzie 1,2, Yingratana A. McLennan 1,2, James Grigsby 3,
Flora Tassone 1,4, David Hessl 1,2, Susan M. Rivera 1,5, Veronica Martinez-Cerdeno 1,6,7 and
Randi J. Hagerman 1,8*
1MIND Institute, University of California Davis Medical Center, Sacramento, CA, United States, 2Department of Psychiatry
and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, United States, 3 School of
Medicine, University of Colorado, Denver, CO, United States, 4Department of Biochemistry and Molecular Medicine,
University of California Davis School of Medicine, Sacramento, CA, United States, 5Department of Psychology, University of
California Davis, Davis, CA, United States, 6Department of Pathology and Laboratory Medicine, Sacramento, CA,
United States, 7 Institute for Pediatric Regenerative Medicine and Shriners Hospitals for Children Northern California,
Sacramento, CA, United States, 8Department of Pediatrics, University of California Davis School of Medicine, Sacramento,
CA, United States
Here we report five cases of male FMR1 premutation carriers who present without clinical
symptoms of the fragile X-associated tremor/ataxia syndrome (FXTAS), but who on MRI
demonstrate white matter hyperintensities in the middle cerebellar peduncles (MCP sign)
and other brain regions, a rare finding. MCP sign is the major radiological feature of
FXTAS; it is therefore remarkable to identify five cases in which this MRI finding is present
in the absence of tremor and ataxia, the major clinical features of FXTAS. Subjects
underwent a detailed neurological evaluation, neuropsychological testing, molecular
testing, and MRI evaluation utilizing T2 imaging described here. Additional white matter
disease was present in the corpus callosum in four of the five cases. However, all cases
were asymptomatic for motor signs of FXTAS.
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INTRODUCTION
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative condition resulting
from a premutation (55-200 CGG repeats) in the FMR1 gene located on the X chromosome
(1, 2). Nearly half of all male FMR1 premutation carriers may develop FXTAS before age 70, with
the disease penetrance rising to 75% after age 80 (3, 4). FXTAS can share symptoms with other
movement disorders; therefore FMR1 gene testing clarifies the diagnosis if an intention tremor
and/or cerebellar ataxia manifests (5). FXTAS typically presents in those who are >50 years of
age. There may be cognitive decline and characteristic radiological findings, including white matter
hyperintensities in the middle cerebellar peduncle (MCP sign) in 60% of males and 16% of females
with FXTAS (4, 6, 7). The MCP sign represents the major radiological diagnostic criterion for
FXTAS and confirms a definite diagnosis of FXTAS when it occurs with tremor and/or ataxia (8).
Additional MRI findings include white matter hyperintensities in the periventricular regions and
splenium of the corpus callosum (CC) (9, 10).
FXTAS is presumably caused by excessive FMR1mRNA that occurs in the premutation, leading
to RNA toxicity (11). This includes sequestration of a number of proteins including DROSHA
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and DGCR8, elevated calcium levels in neurons causing
activation of calpain, and a cascade of molecular changes leading
to miRNA dysregulation, chronic mitochondrial dysfunction and
the formation of FMRpolyG through repeat-associated non-
AUG (RAN) translation (2, 12–17). Classic neuropathological
findings are eosinophilic intranuclear inclusions that are tau and
synuclein negative in neurons, astrocytes, and in Purkinje cells
(18, 19).
Here we report five cases of male premutation carriers who
present without clinical symptoms of FXTAS but demonstrate
the MCP sign, previously seen only in two premutation cases
with minimal or no symptoms reported by Loesch et al. (20).
The Loesch et al. cases included one individual aged 52 years
and another aged 39 years, both showing no clinical symptoms
of neurodegeneration, but presenting with significantMCP signs.
Given the absence of longitudinal data collection in these cases, it
was uncertain how fast FXTAS may develop after the presence of
the MCP sign.
CASES
Case 1 is a 65-year-old, right-handed male with 84 cytosine-
guanine-guanine (CGG) repeats, who denied tremor and ataxia.
On examination his blood pressure was 177/87 mmHg and
his heart rate was 62 bpm. This was consistent with reported
history of and treated with metoprolol and candesartan. His
body mass index (BMI) was 29.3. On neurological examination,
finger-to-nose touching was without tremor and his arm
movements were normal. His deep tendon reflexes were 1 to
2+ in the upper extremities, 3+ at the knees, and 2+ at the
ankles. His temperature sensation was normal and his vibration
sensation was absent in both great toes. Tandem walking was
performed normally. No cognitive abnormalities were present on
neuropsychological examination and no psychiatric symptoms
were reported.
His MRI demonstrated the emergence of a faint MCP
sign (Figure 1A). His CC was slightly thin with minimal
hyperintensity of the splenium of the CC. There was no
significant atrophy but there was a hint of white matter
hyperintensity in the insula bilaterally.
Case 2 is a 50-year-old, right-handed male carrier with 102
CGG repeats who denied tremor and ataxia. He had a history
of multiple concussions from sports injuries in high school and
college.
On examination his blood pressure was 147/82 mmHg and
his heart rate was 48 bpm. His BMI was 25.8. Finger-to-nose
touching was without tremor, and deep tendon reflexes were
symmetrical and 1+ at the upper extremities, 2+ at the knees,
and 2+ at the ankles. His vibration sense was mildly decreased in
the lower extremities. His tandem gait was normal. No cognitive
abnormalities were present on neuropsychological examination
and no psychiatric symptoms were reported.
He presented with the MCP sign on MRI (Figure 1B). He
also had deep cerebellar white matter disease adjacent to the
dentate nuclei, white matter hyperintensity in the splenium of
the CC, mild volume loss involving the vermis and cerebellar
hemispheres, and mesencephalic changes with widened third
ventricle. In addition, an indentation in the superior aspect of
the CC was thought to relate to a small vascular malformation
or aneurysm.
Case 3 is a 62-year-old, right-handed male carrier with 86
CGG repeats who denied tremor and ataxia. On examination
his blood pressure was 125/88 mmHg and his heart rate was 88
bpm.His blood pressure was being controlled with irbesartan and
hydrochlorothiazide. His BMI was 26.9. Finger-to-nose touching
showed no tremor and his tandem walk was without difficulty.
He had slight increased tone on the right and left extremities with
symmetrical movement. Deep tendon reflexes were normal, and
he scored a 2+ in all four extremities. His vibration sense, tactile
sensation, and cold sensation were also normal. No cognitive
abnormalities were present on neuropsychological examination
and no psychiatric symptoms were reported.
The MRI revealed the MCP sign (Figure 1C). Additional
white matter changes were seen in the splenium of the CC.
Case 4 is a 60-year-old right-handed, male carrier with 74
CGG repeats who denied tremor and ataxia. On examination
he had a blood pressure of 152/86 mmHG and a heart rate of
89 bpm. He had a BMI of 27.9. His neurological examination
showed decreased vibration sense in the lower extremities.
Deep tendon reflexes were 1–2+ in the upper and 2+ in
the lower extremities. He had no rest or action tremor, gait
ataxia, or dystonia. No cognitive abnormalities were present on
neuropsychological testing and no psychiatric symptoms were
reported.
The MRI showed mild cerebellar volume loss, with MCP sign
bilaterally (Figure 1D) and subtle inferior cerebellar white matter
changes.
Case 4 visited for follow up examination at age 64, at which
time he had developed a head tremor and mild intention tremor.
He also demonstrated subtle gait ataxia, taking only three steps
on tandem walking. His MRI at age 64 confirmed the previous
findings (Figure 1E).
Case 5 is a 61-year-old, right-handed male carrier with 89
CGG repeats, who denied any history of tremor. He noted that
he had no history of falling but he experienced some instances
of unsteadiness when turning around, possibly attributable to a
4 cm difference in leg lengths secondary to a congenital vascular
malformation in one leg that impacted growth. On examination,
his blood pressure was 107/68 mmHg and his heart rate was
55 bpm. He had a BMI of 26.5. There was no sign of tremor
during finger-to-nose touching. Along with having mild balance
problems while turning, he had instability on tandem walking
during the first few steps. With practice, he was able to perform
at least 6 steps without missteps. He had normal reflexes in
his upper extremities and knees, all +2. His right ankle reflex
was 1+, and there was no reflex in his left ankle. He had
decreased vibration sense bilaterally in both big toes but normal
vibration sense at the ankles bilaterally. Additionally, pinprick
sensation was slightly decreased in the great toe. No cognitive
abnormalities were present on neuropsychological examination
and no psychiatric symptoms were reported.
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FIGURE 1 | MRI Evidence of MCP Sign for Cases 1–5. (A) Axial view of Case 1 showing a hyperintensity of the MCP. (B) Axial view of Case 2 showing a
hyperintensity of the MCP. (C) Axial view of Case 3 showing a hyperintensity of the MCP. (D) Axial view of Case 4 showing a hyperintensity of the MCP at age 60.
(E) Axial view of Case 4 showing a hyperintensity of the MCP at age 64. (F) Axial view of Case 5 showing a hyperintensity of the MCP.
OnMRI, the T2 images showed theMCP sign (Figure 1F) and
white matter hyperintensity in the splenium of the CC. He also
had mild brain atrophy.
METHODS
This study was carried out in accordance with the
recommendations of Institutional Review Board at the
University of California, Davis with written informed consent
from all subjects. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. All subjects gave
written informed consent for publication of their cases. The
protocol was approved by the Institutional Review Board at the
University of California, Davis. The study protocols involved a
detailed medical history and neurological examination, along
with neuropsychological testing, molecular studies of FMR1, and
MRI. All participants were English-speaking men between the
ages of 50 and 70 years, and each was known to be a carrier of
the FMR1 premutation prior to study enrollment.
The neurological examinations were performed by a medical
doctor and included cranial nerve function, tone, rigidity,
reflexes, sensation, extrapyramidal function, and gait. In all five
cases, signs of tremor and ataxia were judged to be absent.
Neuropsychological testing included the Wechsler Adult
Intelligence Scale, Wechsler Memory Scale, and Behavioral
Dyscontrol Scale. Cases 1, 2, 4, and 5 completed the Wechsler
Adult Intelligence Scale, Third Edition (WAIS-III). Case 3 was
tested with the Wechsler Adult Intelligence Scale, Fourth Edition
(WAIS-IV); however the entire test protocol was not completed.
Scores for each case are reported in Table 1.
Psychiatric symptoms were evaluated using the Symptom
Checklist-90-Revised (SCL-90-R) and the Structured Clinical
Interview for DSM-IV (SCID-4).
Genomic DNA was isolated from 3ml peripheral blood
using Gentra Puregene Blood Kit (Qiagen, Valencia, CA)
following standard procedure. CGG trinucleotide repeat size
was determined using a combination of PCR and Southern
blot analysis. PCR was performed using FMR1 specific primers
lying outside the CGG repeat (21). Southern blot was performed
by digestion of 7–10 µg of genomic DNA with the restriction
enzymes Eco RI and Nru I and the digested DNA was separated
on 0.8% agarose gel containing Tris-acetate-EDTA buffer. DNA
was then transferred on a nylon membrane and hybridized with
the FMR1 -specific genomic probe StB12.3 (22).
Presence of the MCP sign was confirmed by neuroradiological
examination of MRI images collected on a Siemens 1.5T or 3T
scanner using pulse sequences. In cases 1, 2, 3, and 5, two different
pulse sequences were used. The first was a turbo spin echo (TSE)
acquired in 48 axial slices of 3mm thickness (no gap) with FOV
of 240 mm2, TR of 4,000ms, TE of 84ms, and matrix size of
384 × 384. The second pulse sequence was a T2-weighted fluid-
attenuated inversion recovery (FLAIR) in which images were
acquired in 104 sagittal slices of 1.9mm thickness (no gap) with
FOV 243mm, 512 Å∼ 512 matrix, TR of 5,000ms, TE of 455ms,
and inversion time 1,700ms. In case 4, the MRI included 1.5mm
corona spoiled gradient echo (SPGR) and 3mm axial proton
density and T2-weighted scans.
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TABLE 1 | Overview of findings for cases 1–5.
Case 1 Case 2 Case 3 Case 4 Case 5
Age at exam (years) 65 50 62 60 61
CGG repeat length 84 102 86 74 89
BMI (kg/m2) 29.3 25.8 27.0 26.5 26.5
Blood pressure (mmHG) 177/87 147/82 125/88 152/86 107/68
Full scale IQ (WAIS-III) 128 120 N/A* 116 116
MRI findings MCP sign, white matter
disease in insula
MCP sign, Arteriovenous
malformation
MCP sign, white matter disease
in splenium of corpus callosum
MCP sign, mild
cerebellar volume loss
MCP sign, white matter
disease in splenium of
corpus callosum
FXTAS symptoms None None None None Slight balance problems,
may be attributed to leg
length difference
*This subject completed four subtests of the WAIS-IV (Wechsler Adult Intelligence Scale, Fourth Edition) that are equivalent to the WASI-II administration (Wechsler Abbreviated Scales
of Intelligence, Second Edition), which yielded a full scale IQ estimate in the range of 108–118.
DISCUSSION
Here we present five cases of male premutation carriers who have
white matter disease in the MCP, a classic sign of FXTAS, but
do not demonstrate clinically significant tremor or ataxia. Case
5 has noted mild balance problems, but he also had a leg length
discrepancy, which may have accounted for this subtle sign.
Although some cases have medical problems such as high blood
pressure, or decreased vibration sense in the lower extremities
typical of mild neuropathy, the major clinical criteria for FXTAS
are not present in these cases. This causes a concern regarding
their prognosis for FXTAS since the radiological findings show
evidence of neurodegeneration but there are no signs of tremor
and ataxia; symptoms that would form the basis of the diagnosis
of FXTAS (10, 23). The recent report by Wang et al. suggests
that there is a continuum of premutation involvement that
starts with brain volume loss by middle adulthood (24). This
may progress into the neurodegeneration of FXTAS, including
white matter disease in the MCP or elsewhere in the brain,
such as the splenium of the CC (25, 26). The cases presented
here demonstrate that the MCP sign can occur even when other
symptoms of FXTAS are not present. In case 4, FXTAS symptoms
developed within 4 years after the appearance of the MCP sign.
It is not clear what exactly is the cause of the white matter
disease, but the RNA toxicity leading to sequestration of critical
proteins for neuronal function, chronic DNA damage repair,
mitochondrial dysfunction, dysregulation of iron transport, and
the production of the neurotoxic FMRpolyG protein from RAN
translation, may all contribute to cell death and white matter
disease (2, 27).
Martinez-Cerdeno et al. suggested that the white matter
disease in the MCP may be related to microhemorrhages (28).
Specifically, they proposed that endothelial cells lining the
capillaries become laden with iron and fail to maintain capillary
integrity, resulting in the release of erythrocytes that, upon
breakdown, release iron. Iron accumulates in the capillaries
and white matter tissue, inducing activation of microglia
and astrocytes, high oxidative state and/or mitochondrial
dysfunction, all leading to myelin loss and axonal degeneration
(19, 27, 29). Microhemorrhages may occur more frequently in
individuals who have hypertension (30). A large-scale study by
Hamlin et al. demonstrated that those with FXTAS are at elevated
risk of developing hypertension (31). It is therefore interesting
that case 1, case 2, and case 4 had hypertension and in two of these
cases this was not adequately treated. Because hypertension is
associated with stroke, central nervous system bleeding and white
matter lesions, these three cases underscore the need for further
research to determine whether there is a similar association
between hypertension and the appearance of the MCP sign (32).
Once there is significant white matter disease, the progression
of further neurological dysfunction is thought to escalate,
although the progression of FXTAS may be quite variable (33).
A recent study by Shickman et al. suggested that motor slowing
may be measurable in asymptomatic premutation carriers before
clinically observed motor or tremor symptoms arise in FXTAS
(34). Future studies that examine white matter changes and
subclinical motor signs of FXTAS may clarify which carriers are
at greatest risk of developing clinical FXTAS symptoms.
A preliminary study demonstrated that the onset of FXTAS
correlates with increased CGG repeats, such that the higher the
repeat number, the earlier the onset of FXTAS symptoms (35).
In the cases presented here, we see both high and medium CGG
repeat numbers associated with the presence of the MCP sign
with no signs of FXTAS. Genomic studies are needed to decipher
if there are other additive deleterious or protective allelic variants
or mutations, which can cause early onset of white matter disease
or protect against the clinical manifestations of FXTAS.
In the cases reported here, the neurological symptoms of
tremor and ataxia are nonexistent so we do not have the
clinical findings for a diagnosis of FXTAS. We consider these
patients to be at high risk for FXTAS, or pre-FXTAS, because
they already have the MRI findings and therefore evidence of
neurodegeneration. We have seen a progression of symptoms in
Case 4, who had developed FXTAS at his 4-year follow up, and
we will continue to follow the remaining four subjects.
CONCLUDING REMARKS
The presence of the MCP sign may be more common than
originally thought in premutation carriers without neurological
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symptoms. Their follow-up will guide our recommendations
for these carriers in the future. We suspect that avoidance of
toxins (such as excessive alcohol, opioids, and inhaled anesthetic
agents) and other insults (such as the hypoxia of sleep apnea, or
head trauma), in addition to exercise and treatment of medical
problems including hypertension or obesity may help to stabilize
or slow the progression of FXTAS even in those with white
matter disease as reported here (36, 37). Perhaps supplements
such as antioxidants, epicatechins or other prophylactic measures
may improve mitochondrial function or white matter disease
(38, 39). Longitudinal research to uncover the risk and protective
factors underlying the development and progression of FXTAS
and the development of treatment targets is needed to help these
vulnerable individuals with the premutation.
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